1. Home
  2. ALLO vs NOAH Comparison

ALLO vs NOAH Comparison

Compare ALLO & NOAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.06

Market Cap

707.6M

Sector

Health Care

ML Signal

HOLD

NOAH

Noah Holdings Limited

HOLD

Current Price

$10.34

Market Cap

653.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLO
NOAH
Founded
2017
2005
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
707.6M
653.4M
IPO Year
2018
2010

Fundamental Metrics

Financial Performance
Metric
ALLO
NOAH
Price
$2.06
$10.34
Analyst Decision
Strong Buy
Hold
Analyst Count
15
2
Target Price
$8.35
$11.00
AVG Volume (30 Days)
7.8M
69.2K
Earning Date
05-07-2026
05-27-2026
Dividend Yield
N/A
5.66%
EPS Growth
34.09
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$142,416.42
$5.71
P/E Ratio
N/A
$13.29
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$9.53
52 Week High
$4.46
$12.84

Technical Indicators

Market Signals
Indicator
ALLO
NOAH
Relative Strength Index (RSI) 52.33 47.62
Support Level $1.85 $9.83
Resistance Level $2.36 $10.84
Average True Range (ATR) 0.13 0.28
MACD 0.03 0.01
Stochastic Oscillator 74.12 54.01

Price Performance

Historical Comparison
ALLO
NOAH

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

About NOAH Noah Holdings Limited

Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.

Share on Social Networks: